View Abstract

A1516 - 18 FDG PET CT and Sarcoidosis
Author Block: M. Carneiro1, C. H. Costa2, R. L. R. Alves3, F. M. Anselmo1, B. R. Silva4, E. J. Bessa5, L. Bruno1; 1UERJ, Rio de Janeiro, Brazil, 2Pneumologia, HUPE, Rio de Janeiro, Brazil, 3Pulmonology Department, UERJ, Rio de Janeiro, Brazil, 4PNEUMOLOGY, UERJ, RIO DE JANEIRO, Brazil, 5UERJ - Brazil, Rio de Janeiro, Brazil.
Introduction: 18 fluorodeoxyglucose (FDG) positron emission tomography - computed tomography (PET-CT) is an imaging method that uses high glucose metabolism as an auxiliary tool to monitor oncological diseases. Several studies have demonstrated its usefulness in patients with sarcoidosis both to identify areas of disease activity, extrapulmonary sites, favorable sites for biopsy and to differentiate fibrosis in radiological stage 4 from active sarcoidosis areas. Objective: To describe findings in PET-CT of patients with sarcoidosis and its contribution in clinical practice in the identification of active or remission disease. Methods: A prospective study involving 34 patients with sarcoidosis diagnosed and followed at Piquet Carneiro Polyclinic / UERJ - Rio de Janeiro / Brazil underwent 18 FDG PET-CT with images from the skull to the middle of the thighs, from November 2016 to April 2017. Results: 80% female, mean age 50 ± 10 years .PET-CT lesions demonstrated uptake of the radiotracer in 12 patients. Extrapulmonary sites were observed in 8 exams. Of these, 2 in the spleen, 2 in bones, 2 in subcutaneous tissue, 6 in abdominal and pelvic lymph nodes, 2 in axillary lymph nodes and 1 in cervical chain. The SUV max (standardized uptake values) ranged from 1.9 to 16.1. Most of the positive findings (75%) were in patients with radiographs showing stage II. 3 patients had their treatment changed after demonstration of metabolic activity by PET CT.Conclusion: The 18 FDG PET-CT proved to be an important auxiliary tool in monitoring patients with sarcoidosis, sometimes changing pre-established therapy.